Project: Covalently linked-ADC as a new and innovative technology for cancer therapy
The enzymatic covalently conjugated drugs, CovIsoLink allows the coupling of 2 drug molecules on a specific site of 1 monoclonal antibody. We aim to validate the proof of concept of our new & patented technology compared to the existing T-DM1 ADC for breast cancer developed by chemical conjugation. The new CovHer2-ADC will be studied in vitro & in vivo using T-DM1 ADC as a reference. The results expected are homogenous ADC preparations rather than mixtures resulting in greater efficacy & safety.
| Acronym | CovIsoLink (Reference Number: 10478) |
| Duration | 01/09/2016 - 01/09/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 24208 | COVALAB | Coordinator | France |
| 24209 | IONTAS Ltd | Partner | United Kingdom |
| 24210 | Université Claude Bernard Lyon 1 | Partner | France |